Jade Biosciences, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Jade Biosciences, Inc. (JBIO) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$2.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- Jade Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $2.83M, a 232.78% increase year-over-year.
- Jade Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$5.44M, a 1173.77% decline year-over-year.
- Jade Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $10.20M, a 20296.00% increase year-over-year.
- Jade Biosciences, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $413.00K, a 92.09% increase year-over-year.
- Jade Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $11.97M.
- Jade Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$299.00K.
- Jade Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$483.00K.
- Jade Biosciences, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$4.68M, a 168.23% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$2.61M 10-Q · filed 2026-08-10 | $7.59M derived: sum of 3 quarters · filed 2026-08-10 | $8.00M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$5.44M 10-Q · filed 2026-05-07 | $4.75M derived: sum of 2 quarters · filed 2026-05-07 | $5.17M derived: sum of 3 quarters · filed 2026-05-07 | $6.02M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $10.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $10.61M derived: sum of 2 quarters · filed 2026-03-06 | $11.46M derived: sum of 3 quarters · filed 2026-08-10 | $11.97M 10-K · filed 2026-03-06 | |
| 2025-09-30 | $413.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.26M derived: sum of 2 quarters · filed 2026-08-10 | $1.77M 10-Q · filed 2025-11-14 | $1.82M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $851.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.36M 10-Q · filed 2026-08-10 | $1.41M derived: sum of 3 quarters · filed 2026-08-10 | $1.62M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $507.00K 10-Q · filed 2026-05-07 | -$331.00K 10-Q · filed 2025-04-25 | $557.00K derived: sum of 2 quarters · filed 2026-05-07 | $772.00K derived: sum of 3 quarters · filed 2026-05-07 | $3.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $50.00K derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | $265.00K 10-K · filed 2026-03-06 | $2.92M derived: sum of 3 quarters · filed 2026-03-06 | -$299.00K 10-K · filed 2025-03-27 | |
| 2024-09-30 | $215.00K 10-Q · filed 2025-11-14 | $2.87M derived: sum of 2 quarters · filed 2025-11-14 | $82.00K 10-Q · filed 2024-11-12 | $4.37M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $4.76M 10-Q · filed 2024-08-12 | $4.15M derived: sum of 3 quarters · filed 2025-04-25 | $4.18M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2024-03-31 | $2.11M 10-Q · filed 2025-04-25 | $1.50M derived: sum of 2 quarters · filed 2025-04-25 | $1.53M derived: sum of 3 quarters · filed 2025-04-25 | $2.27M derived: sum of 4 quarters · filed 2025-04-25 | |
| 2023-12-31 | -$611.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$581.00K derived: sum of 2 quarters · filed 2025-03-27 | $153.00K derived: sum of 3 quarters · filed 2025-03-27 | -$483.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $764.00K derived: sum of 2 quarters · filed 2024-11-12 | $128.00K 10-Q · filed 2024-11-12 | -$174.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $734.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $98.00K 10-Q · filed 2024-08-12 | -$204.00K derived: sum of 3 quarters · filed 2024-08-12 | $914.00K derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$636.00K 10-Q · filed 2024-05-13 | -$938.00K derived: sum of 2 quarters · filed 2024-05-13 | $180.00K derived: sum of 3 quarters · filed 2024-05-13 | -$3.18M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$302.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $816.00K derived: sum of 2 quarters · filed 2024-03-25 | -$2.55M derived: sum of 3 quarters · filed 2024-03-25 | -$4.68M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$2.25M derived: sum of 2 quarters · filed 2023-11-13 | -$4.38M 10-Q · filed 2023-11-13 | $359.00K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$5.49M 10-Q · filed 2023-08-14 | -$759.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.31M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$2.13M 10-Q · filed 2023-05-15 | $2.60M derived: sum of 2 quarters · filed 2023-05-15 | $4.67M derived: sum of 3 quarters · filed 2023-05-15 | $3.87M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $4.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $6.80M derived: sum of 2 quarters · filed 2023-03-29 | $6.00M derived: sum of 3 quarters · filed 2023-03-29 | $6.86M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.26M derived: sum of 2 quarters · filed 2022-11-14 | $2.12M 10-Q · filed 2022-11-14 | $1.99M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$804.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $56.00K 10-Q · filed 2022-08-15 | -$76.00K derived: sum of 3 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $860.00K 10-Q · filed 2022-05-16 | $728.00K derived: sum of 2 quarters · filed 2022-05-16 | |||
| 2020-12-31 | -$132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $103.00K 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $235.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |